Parkinsonism-Hyperpyrexia Syndrome in Parkinson’s Disease

  • Daniel E. Huddleston
  • Stewart A. FactorEmail author
Part of the Current Clinical Neurology book series (CCNEU)


Parkinsonism-hyperpyrexia syndrome (PHS) is a rare but potentially life-threatening complication of Parkinson’s disease (PD). PHS was first described in 1981 and has been reported in dozens of cases since then. The clinical presentation of PHS includes hyperpyrexia, rigidity, altered consciousness, dysautonomia, leukocytosis, and elevated creatine kinase. Although PHS and NMS are phenotypically nearly identical, PHS is a distinct entity in that it is triggered by removal or effective loss of dopaminergic therapy in a parkinsonian patient. The mainstay of PHS treatment is rapid replacement of effective anti-parkinsonian therapy. While abrupt levodopa withdrawal is the classic trigger of PHS, a variety of other inciting scenarios have been described. The pathophysiology underlying PHS is generally accepted to be a hypo-dopaminergic state, and its clinical features can be explained as sequelae of central dopamine depletion. PHS is a neurological emergency, with significant morbidity and mortality. Early recognition and rapid reintroduction of anti-parkinsonian medications are keys to the successful management of this syndrome.


Deep Brain Stimulation Neuroleptic Malignant Syndrome Dopaminergic Medication Drug Holiday Dopaminergic Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Supplementary material

Video 3.1 (47,230) KB


  1. 1.
    Factor SA. Fatal Parkinsonism-hyperpyrexia syndrome in a Parkinson’s disease patient while actively treated with deep brain stimulation. Mov Disord. 2007;22:148–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Delay J, Pichot P, Lemperiere T, Elissalde B, Peigne F. A non-phenothiazine and non-reserpine major neuroleptic, haloperidol, in the treatment of psychoses. Ann Med Psychol (Paris). 1960;118:145–52.Google Scholar
  3. 3.
    Delay J, Denicker P. Drug induced extrapyramidal syndromes. In: Vinken P, Bruyun G, editors. Handbook of clinical neurology. Amsterdam: North Holland; 1968. p. 258–9.Google Scholar
  4. 4.
    Factor S. Neuroleptic malignant syndrome. In: Factor S, Lang A, Weiner W, editors. Drug induced movement disorders. 2nd ed. Mount Kisco, NY: Blackwell Publishing; 2005. p. 174–212.CrossRefGoogle Scholar
  5. 5.
    Caroff SN. The neuroleptic malignant syndrome. J Clin Psychiatry. 1980;41:79–83.PubMedGoogle Scholar
  6. 6.
    Shalev A, Munitz H. The neuroleptic malignant syndrome: agent and host interaction. Acta Psychiatr Scand. 1986;73:337–47.PubMedCrossRefGoogle Scholar
  7. 7.
    Rosebush P, Stewart T. A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am J Psychiatry. 1989;146:717–25.PubMedGoogle Scholar
  8. 8.
    Kurlan R, Hamill R, Shoulson I. Neuroleptic malignant syndrome. Clin Neuropharmacol. 1984;7:109–20.PubMedCrossRefGoogle Scholar
  9. 9.
    Mueller P. Diagnosis and treatment of neuroleptic malignant syndrome: a review. Neuroview. 1987;3:1–5.Google Scholar
  10. 10.
    Burke RE, Fahn S, Mayeux R, Weinberg H, Louis K, Willner JH. Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease. Neurology. 1981;31:1022–5.PubMedCrossRefGoogle Scholar
  11. 11.
    Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148:705–13.PubMedGoogle Scholar
  12. 12.
    Kosten TR, Kleber HD. Rapid death during cocaine abuse: a variant of the neuroleptic malignant syndrome? Am J Drug Alcohol Abuse. 1988;14:335–46.PubMedCrossRefGoogle Scholar
  13. 13.
    Toro M, Matsuda O, Mikizuich K, Sugano K. Neuroleptic malignant syndrome-like state following withdrawal of antiparkinsonian drugs. J Nerv Ment Dis. 1981;169:324–7.CrossRefGoogle Scholar
  14. 14.
    Friedman JH, Feinberg SS, Feldman RG. A neuroleptic malignant like syndrome due to levodopa therapy withdrawal. JAMA. 1985;254:2792–5.PubMedCrossRefGoogle Scholar
  15. 15.
    Gordon PH, Frucht SJ. Neuroleptic malignant syndrome in advanced Parkinson’s disease. Mov Disord. 2001;16:960–2.PubMedCrossRefGoogle Scholar
  16. 16.
    Pfeiffer RF, Sucha EL. “On-off”-induced lethal hyperthermia. Mov Disord. 1989;4:338–41.PubMedCrossRefGoogle Scholar
  17. 17.
    Serrano-Duenas M. Neuroleptic malignant syndrome-like, or—dopaminergic malignant syndrome—due to levodopa therapy withdrawal; clinical features in 11 patients. Parkinsonism Relat Disord. 2003;9:175–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Keyser DL, Rodnitzky RL. Neuroleptic malignant syndrome in Parkinson’s disease after withdrawal or alteration of dopaminergic therapy. Arch Intern Med. 1991;151:794–6.PubMedCrossRefGoogle Scholar
  19. 19.
    Newman EJ, Grosset DG, Kennedy PG. The parkinsonism-hyperpyrexia syndrome. Neurocrit Care. 2009;10:136–40.PubMedCrossRefGoogle Scholar
  20. 20.
    Onofrj M, Bonanni L, Cossu G, Manca D, Stocchi F, Thomas A. Emergencies in parkinsonism: akinetic crisis, life-threatening dyskinesias, and polyneuropathy during L-Dopa gel treatment. Parkinsonism Relat Disord. 2009;15 Suppl 3:S233–6.PubMedCrossRefGoogle Scholar
  21. 21.
    Kipps CM, Fung VS, Grattan-Smith P, de Moore GM, Morris JG. Movement disorder emergencies. Mov Disord. 2005;20:322–34.PubMedCrossRefGoogle Scholar
  22. 22.
    Robottom BJ, Weiner WJ, Factor SA. Movement disorders emergencies part 1: hypokinetic disorders. Arch Neurol. 2011;68:567–72.PubMedCrossRefGoogle Scholar
  23. 23.
    Sechi GP, Tanda F, Mutani R. Fatal hyperpyrexia after withdrawal of levodopa. Neurology. 1984;34:249–51.PubMedCrossRefGoogle Scholar
  24. 24.
    Figa-Talamanca L, Gualandi C, Di Meo L, Di Battista G, Neri G, Lo Russo F. Hyperthermia after discontinuance of levodopa and bromocriptine therapy: impaired dopamine receptors a possible cause. Neurology. 1985;35:258–61.PubMedCrossRefGoogle Scholar
  25. 25.
    Hirschorn KA, Greenberg HS. Successful treatment of levodopa-induced myoclonus and levodopa withdrawal-induced neuroleptic malignant syndrome; a case report. Clin Neuropharmacol. 1988;11:278–81.PubMedCrossRefGoogle Scholar
  26. 26.
    Mayeux R, Stern Y, Mulvey K, Cote L. Reappraisal of temporary levodopa withdrawal (“drug holiday”) in Parkinson’s disease. N Engl J Med. 1985;313:724–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Factor SA, Molho ES, Podskalny GD, Brown D. Parkinson’s disease: drug-induced psychiatric states. Adv Neurol. 1995;65:115–38.PubMedGoogle Scholar
  28. 28.
    Iwuagwu CU, Riley D, Bonoma RA. Neuroleptic malignant-like syndrome in an elderly patient caused by abrupt withdrawal of tolcapone, a-catechol-o-methyl transferase inhibitor. Am J Med. 2000;108:517–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Cunningham MA, Darby DG, Donnan GA. Controlled-release delivery of L-dopa associated with nonfatal hyperthermia, rigidity, and autonomic dysfunction. Neurology. 1991;41:942–3.PubMedCrossRefGoogle Scholar
  30. 30.
    Henderson VW, Wooten GF. Neuroleptic malignant syndrome: a pathogenetic role for dopamine receptor blockade? Neurology. 1981;31:132–7.PubMedCrossRefGoogle Scholar
  31. 31.
    Mizuta E, Yamasaki S, Nakatake M, Kuno S. Neuroleptic malignant syndrome in a parkinsonian woman during the premenstrual period. Neurology. 1993;43:1048–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Cao L, Katz RH. Acute hypernatremia and neuroleptic malignant syndrome in Parkinson disease. Am J Med Sci. 1999;318:67–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Bonnici A, Ruiner CE, St-Laurent L, Hornstein D. An interaction between levodopa and enteral nutrition resulting in neuroleptic malignant-like syndrome and prolonged ICU stay. Ann Pharmacother. 2010;44:1504–7.PubMedCrossRefGoogle Scholar
  34. 34.
    The Deep Brain Stimulation For Parkinson’s Disease Study Group. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson’s disease. N Engl J Med. 2001;345:956–63.CrossRefGoogle Scholar
  35. 35.
    Vingerhoets FJ, Villemure JG, Temperli P, Pollo C, Pralong E, Ghika J. Subthalamic DBS replaces levodopa in Parkinson’s disease: two-year follow-up. Neurology. 2002;58:396–401.PubMedCrossRefGoogle Scholar
  36. 36.
    Kleiner-Fisman G, Saint-Cyr JA, Miyasaki J, Lozano A, Lang AE. Subthalamic DBS replaces levodopa in Parkinson’s disease. Neurology. 2002;59:1293–4.PubMedCrossRefGoogle Scholar
  37. 37.
    Kadowaki T, Hashimoto K, Suzuki K, Watanabe Y, Hirata K. Case report: recurrent parkinsonism-hyperpyrexia syndrome following discontinuation of subthalamic deep brain stimulation. Mov Disord. 2011;26(8):1561–2. 10.1002/mds.23596.PubMedCrossRefGoogle Scholar
  38. 38.
    Kim JH, Kwon TH, Koh SB, Park JY. Parkinsonism-hyperpyrexia syndrome after deep brain stimulation surgery: case report. Neurosurgery. 2010;66:E1029.PubMedCrossRefGoogle Scholar
  39. 39.
    Sato Y, Asoh T, Metoki N, Satoh K. Efficacy of methylprednisolone pulse therapy on neuroleptic malignant syndrome in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2003;74:574–6.PubMedCrossRefGoogle Scholar
  40. 40.
    Ueda M, Hamamoto M, Nagayama H, et al. Susceptibility to neuroleptic malignant syndrome in Parkinson’s disease. Neurology. 1999;52:777–81.PubMedCrossRefGoogle Scholar
  41. 41.
    Ueda M, Hamamoto M, Nagayama H, Okubo S, Amemiya S, Katayama Y. Biochemical alterations during medication withdrawal in Parkinson’s disease with and without neuroleptic malignant-like syndrome. J Neurol Neurosurg Psychiatry. 2001;71:111–3.PubMedCrossRefGoogle Scholar
  42. 42.
    Kuno S, Komure O, Mizuta E, Yamasaki S, Nishitani H. Neuroleptic malignant syndrome associated with withdrawal of antiparkinsonian drugs. In: Nagatsu T, Fisher A, Yoshida M, editors. Basic clinical and therapeutic aspects of Alzheimer’s and Parkinson’s disease. New York: Plenum Press; 1990. p. 245–8.CrossRefGoogle Scholar
  43. 43.
    Yamawaki Y, Ogawa N. Successful treatment of levodopa-induced neuroleptic malignant syndrome (NMS) and disseminated intravascular coagulation (DIC) in a patient with Parkinson’s disease. Intern Med. 1992;31:1298–302.PubMedCrossRefGoogle Scholar
  44. 44.
    The Parkinson Study Group. Levodopa and the progression of Parkinson’s disease. N Eng J Med. 2004;351:2498–508.CrossRefGoogle Scholar
  45. 45.
    Genis D. Neuroleptic malignant syndrome: impaired dopaminergic systems? Neurology. 1985;35:1806.PubMedCrossRefGoogle Scholar
  46. 46.
    Konagaya M, Goto Y, Matsuoka Y, Konishi T, Konagaya Y. Neuroleptic malignant syndrome-like condition in multiple system atrophy. J Neurol Neurosurg Psychiatry. 1997;63:120–1.PubMedCrossRefGoogle Scholar
  47. 47.
    Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson’s disease. Mov Disord. 2000;15:201–11.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of Neurology and Emory Movement Disorders ClinicEmory University School of MedicineAtlantaUSA
  2. 2.Department of NeurologyEmory University School of MedicineAtlantaUSA

Personalised recommendations